Benefits
Treatment of selected vitamin B12 deficiencies associated with malabsorption.
Named U.S. presentation only; selected label sections.
Peptide library
Vitamin B12
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
The named U.S. product label is the appropriate source for its approved use, contraindications and handling. This cyanocobalamin injection label reports peak plasma levels within one hour after IM injection, not an elimination half-life. Urinary recovery and long-term liver stores are different measures; no numeric half-life is established by this label. A label extraction is not an independent appraisal of every supporting trial or approval of other products with the same ingredient.
About this assessment
Named U.S. product label sections assessed.
Product-specific editorial extraction. Complete clinical review and clinician sign-off remain pending; other jurisdictions are not inferred.
Editorial assessment · 2026-09-07
Who was studied
The population specified by this product label; other indications and jurisdictions remain outside this check.
What the sources found
Treatment of selected vitamin B12 deficiencies associated with malabsorption.
Regulatory scope
U.S. label record for ANDA209429. This does not confer authorization on other products using the ingredient name.
What remains unknown
Named-product label sections were expanded for pharmacokinetics, contraindications and selected handling or interaction details on September 7, 2026. This is not a complete trial-program appraisal or clinician sign-off. Other formulations, patient-specific decisions and other jurisdictions require separate assessment.
How it works
Henry Schein/Somerset cyanocobalamin 1,000 mcg/mL multidose injection
Consult the product label for pharmacology. A mechanism does not extend its approved indications.
Approved product exists
Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.
Reported adverse effects
- Parenteral anaphylaxis and hypokalemia during intensive anemia treatment are reported; this product contains benzyl alcohol.
Named U.S. presentation only; selected label sections.
Contraindications
- This cyanocobalamin injection: sensitivity to cobalt or vitamin B12. A deficiency diagnosis and monitoring are needed; nutrition intake targets are not replacement-treatment doses.
Approved product exists
Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.
Sources used for this snapshot
Claim-by-claim evidence
Adverseeffects
Parenteral anaphylaxis and hypokalemia during intensive anemia treatment are reported; this product contains benzyl alcohol.
Named U.S. presentation only; selected label sections.
Storage
This cyanocobalamin presentation: 20–25°C, permitted excursions 15–30°C; protect from light. Other B12 forms require their own instructions.
Named U.S. presentation only; selected label sections.
Pharmacokinetics
This cyanocobalamin injection label reports peak plasma levels within one hour after IM injection, not an elimination half-life. Urinary recovery and long-term liver stores are different measures; no numeric half-life is established by this label.
Named U.S. product only; label revision 20251016. Educational extraction, not complete clinical review.
Contraindications
This cyanocobalamin injection: sensitivity to cobalt or vitamin B12. A deficiency diagnosis and monitoring are needed; nutrition intake targets are not replacement-treatment doses.
Named U.S. product only; label revision 20251016. Educational extraction, not complete clinical review.
References
Stabler SP. Vitamin B12 deficiency. NEJM. 2013.
PMID: 23301732
Henry Schein/Somerset cyanocobalamin 1,000 mcg/mL multidose injection. U.S. structured product label, effective 20251016. Selected sections only.
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.